Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-term Follow-up Study Evaluating the Safety and Efficacy of Subjects With β-thalassemia Treated With CS-101 Transplantation

NCT06717932 is registered in ClinicalTrials.gov with CorrectSequence Therapeutics Co., Ltd as lead sponsor.

NCT NCT06717932
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06717932 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-term Follow-up Study Evaluating the Safety and Efficacy of Subjects With β-thalassemia Treated With CS-101 Transplantation
Lead sponsor
CorrectSequence Therapeutics Co., Ltd
Phase
Observational
Overall status
Enrolling by invitation
Start date
May 15, 2025
Completion date
November 30, 2039
Enrollment
8 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

beta-thalassemia